PEOPLE People By Staff Monday, August 15, 2016 12:00 AM James Mazzo James Mazzo to Head Zeiss Meditec’s Newly Consolidated Ophthalmology Unit JENA, Germany—James Mazzo will join Carl Zeiss Meditec as global president of ophthalmology with responsibility for the company’s new strategic business unit ophthalmology as well as Carl Zeiss Meditec’s U.S. sales and service center. A prominent industry executive, Mazzo has over 35 years of ophthalmic experience. He most recently served as executive chair and CEO of AcuFocus, developer of the Kamra corneal inlay and IC-8 IOL. Prior to that, Mazzo spent over 20 years leading Allergan’s North American and European eyecare organizations. He led the public spin-off of AMO as chairman/CEO, building that organization into a leading company in refractive, cataract and eyecare products. In 2009, Abbott Labs purchased AMO and Mazzo was selected as executive vice president to lead Abbott’s global ophthalmology business. He left Abbott in 2013 to join AcuFocus and serve as executive chair of Neurotech. In a joint statement by executive and supervisory board of Carl Zeiss Meditec AG, Dr. Ludwin Monz, president and CEO, and Dr. Michael Kaschke, chairman of the supervisory board, commented, “We are excited to have Mr. Mazzo, one of the best experts in the ophthalmology industry join the Zeiss family. The reorganization and new leadership of the ophthalmology business will allow Carl Zeiss Meditec to extend the offering for ophthalmology and optometric customers globally. We see particular opportunities in extending the business in North America and parts of Asia.” Timothy Mayhew Gunnar Spaulding Luxury Optical Holdings Names Timothy Mayhew CEO NEW YORK—Luxury Optical Holdings (LOH) has named Timothy Mayhew as CEO, effective immediately. Additionally, the company announced the adoption of a strategic plan to set LOH on course for sustained growth and profitability. Mayhew will lead the execution of this growth strategy by raising growth capital and implementing a long-term store expansion plan which involves a shift toward investing in its brands and building its wholesale business, the company said in a statement. The strategy will focus on maximizing the potential of LOH brands Robert Marc and Morgenthal Frederics by offering “an unparalleled product selection and customer experience in the premium optical retail market,” the statement continued. In addition, the capital injection from LOH’s major shareholders, aPriori Capital Partners and Goode Partners, will go toward strengthening the company’s balance sheet and investing into personnel, marketing, product development and stores, LOH said. Reporting directly to Mayhew is Glenn Reisch, president of LOH and a seven-year veteran who has led the business through tremendous growth changes. Concurrently, Gunnar Spaulding has been named president of Robert Marc and will also be reporting directly to Mayhew. Mayhew, who was most recently president and CEO of Easton-Bell Sports, has spent his career partnering with founders to build brands. He also previously served as chairman of 1-800 CONTACTS, and during his tenure there as chairman, 1-800 CONTACTS became an omni-channel retailer, started Glasses.com which was ultimately sold to WellPoint for $900 million. Alan Waterhouse AcuFocus Appoints Alan Waterhouse President and COO; William Link, PhD Becomes Chairman of the Board IRVINE, Calif.—AcuFocus, developer of the Kamra corneal inlay and IC-8 IOL, announced that Alan Waterhouse has been appointed president and chief operating officer (COO) and William Link, PhD, has joined the company as chairman of the board. Waterhouse will also take a seat on the board of directors. Waterhouse and Link will replace Jim Mazzo, current chairman and chief executive officer, who will join Carl Zeiss Meditec as global president of ophthalmology effective Aug. 1, 2016. Waterhouse brings to AcuFocus more than 21 years of health care experience, having joined the company as COO in 2015. In past roles, he has served as vice president or president of Abbott Labs, Advanced Medical Optics, Cardinal Health (Pyxis Corp./PCI Services), and the Asteres Corp. He has participated in over a dozen M&A deals, raised significant venture capital, and been a part of management teams that have created over $4.5B in market value. Link is managing director and co-founder of Versant Ventures, a health care investment firm. He has more than two decades of operations experience in the health care industry and extensive knowledge of the ophthalmic market. The Kamra inlay helps presbyopic patients restore their near vision while maintaining their distance vision. The IC-8 IOL provides a range of vision across various distances, from near to far, and is specifically designed for patients with cataracts. It is not yet approved by the FDA for use in the U.S. Frank Shields ReVision Optics Names Frank Shields VP of Sales Worldwide LAKE FOREST, Calif.—ReVision Optics, Inc., announced the appointment of Frank Shields to the newly created position of vice president of sales worldwide. He will be responsible for leading the commercialization of the Raindrop Near Vision Inlay in the U.S. and expanding international sales. The Raindrop Near Vision Inlay is a device implanted in the cornea of one eye to improve near vision in certain patients with presbyopia. It was recently approved by the U.S. Food and Drug Administration. Shields brings more than 25 years of experience in surgical sales at leading ophthalmic companies and has been instrumental in the launch of several leading ophthalmic lens products. He served at Bausch + Lomb Surgical for 17 years. Most recently, he served as regional sales manager, and prior to that he was executive sales representative prior. He also served as senior surgical sales representatives at Chiron Vision. Beth Marsh Beth Marsh Joins Shire’s Ophthalmics Team as Commercial Strategy Lead LEXINGTON, Mass.—Beth Marsh joined Shire’s ophthalmic team as commercial strategy lead for SHP640, the development program for a drug being investigated to treat infectious conjunctivitis (adenoviral and bacterial). Marsh comes to Shire with more than 20 years’ experience. Most recently, she was working at her own consulting firm to assist development-stage ophthalmic pharmaceutical and medical device companies prepare for commercial success, acquisition or investment. She’s held leadership roles across key functions and was a key team member working on the commercial launches for the ophthalmic business units at Johnson & Johnson, Novartis, Santen and Akorn. As commercial lead strategy lead, she will be responsible for building the commercial launch plan for SHP640 as the product advances through the development cycle at Shire, the company said.